FDA approves Erelzi, a biosimilar to Enbrel - FDA Press Releases

The U.S. Food and Drug Administration today approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998.

from Food and Drug Administration--Press Releases http://ift.tt/2c2NjRE
via IFTTT